PurpleDaisy Logo
PurpleDaisyResources
BiomarkersReference MatrixLab PanelsCalculatorsCompareGuidesBlog
Download on the App Store
BiomarkersReference MatrixLab PanelsCalculatorsCompareGuidesBlog

Biomarker Encyclopedia

500+ Items
Master Catalogs
  • All 500+ Biomarkers Directory
  • Longevity Reference MatrixPDF
Categories (500+ Markers)
  • Cardiovascular & Lipidology
  • Metabolic & Glycemic Control
  • Renal Physiology & Electrolytes
  • Hepatic & Biliary Function
  • Hematology & CBC
  • Iron Metabolism & Oxygen Transport
  • Endocrinology & Hormones
  • Micronutrients & Vitamins
  • Immunology & Longevity Clocks
Download Meridian on the App Store
Home/Biomarkers/Metabolic & Glycemic Control/HbA1c
Metabolic & Glycemic ControlLong-Term Glycemic Glycation

Hemoglobin A1c (HbA1c)

Hemoglobin A1c quantifies the percentage of circulating hemoglobin molecules with non-enzymatically glycated N-terminal valine residues, integrating mean blood glucose concentrations over the prior 90 to 120 days.

Standard Range< 5.7% (Prediabetes: 5.7 - 6.4%, Diabetes: >= 6.5%)
Optimal Longevity4.8% - 5.2%
Measurement Unit%
Organ SystemLong-Term Glycemic Glycation
Routine Panels:Diabetes ScreenComprehensive Longevity PanelMetabolic Profile

Standard vs. Optimal Reference Ranges%

Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.

Interactive Range Analyzer
Unit: %
%
Presets:
3 %Optimal Zone Target9 %
Standard Commercial Normal(5.8 %)

Within standard population reference range, though above optimal longevity targets.

Standard Reference Interval

< 5.7% (Prediabetes: 5.7 - 6.4%, Diabetes: >= 6.5%)

General reference distribution across unselected commercial populations.

Optimal Longevity Target

4.8% - 5.2%

Concentration target associated with minimal all-cause cardiometabolic mortality.

Molecular Mechanism & Clinical Purpose

Glucose diffuses across erythrocyte membranes via GLUT1 transporters and condenses with the beta-chain amino group of hemoglobin, forming an unstable Schiff base that undergoes irreversible Amadori rearrangement to form HbA1c.

Differential Diagnosis

Elevated Levels (HbA1c High)

  • •Type 1 and Type 2 Diabetes Mellitus
  • •Iron deficiency anemia (falsely prolongs RBC lifespan)
  • •Splenectomy / Decreased erythrocyte turnover

Low Levels (HbA1c Low)

  • •Hemolytic anemias / Shortened RBC survival
  • •Chronic blood loss or recent blood transfusion
  • •G6PD deficiency
  • •High-dose Vitamin C or E supplementation (assay interference)

Technical Reference & Deep Dive

Biochemistry & Enzymatic Pathways
The physiological homeostasis of Hemoglobin A1c (HbA1c) is governed by pancreatic islet beta-cell secretion, hepatic gluconeogenesis, skeletal muscle GLUT4 glucose transporter translocation, and peripheral insulin sensitivity. Cellular signal transduction occurs via the insulin receptor tyrosine kinase (IRTK), triggering phosphorylation of IRS-1 and IRS-2, which activates the phosphatidylinositol 3-kinase (PI3K)-Akt cascade and downregulates FOXO1 transcription factors. Impaired signaling causes systemic hyperinsulinemia, attenuated mitochondrial beta-oxidation, and accelerated hepatic de novo lipogenesis (DNL).
Longevity Risk Architecture & Epidemiology
HbA1c levels between 4.8% and 5.2% associate with lowest all-cause mortality in non-diabetic cohorts. Higher levels accelerate tissue aging via cross-linking of vascular extracellular matrix proteins.
Pre-Analytical Caveats & Diagnostic Workup

Pre-Analytical Considerations:

Strict 10 to 12 hour overnight water-only fasting is mandatory for baseline metabolic quantification. Acute psychological stress, acute infectious illness, and sleep deprivation (<6 hours) transiently elevate cortisol and catecholamines, falsely elevating glycemic markers. For glucose and insulin testing, draw blood into sodium fluoride/potassium oxalate tubes or separate serum promptly within 30 minutes to prevent ongoing in vitro red blood cell glycolysis.

Reflexive Testing Protocol:

  • Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and HOMA-Beta calculations
  • Continuous Glucose Monitoring (CGM) 14-day wear to evaluate glycemic variability and postprandial excursions
  • Fasting C-Peptide and high-sensitivity Troponin/hs-CRP to differentiate insulin resistance from beta-cell exhaustion
  • Oral Glucose Tolerance Test (OGTT) with simultaneous 0, 30, 60, and 120-minute insulin assays
  • Abdominal ultrasound or FibroScan to evaluate hepatic steatosis and non-alcoholic fatty liver disease (MASLD)
Clinical Citations & Primary Literature (1)
  • [1]Association of Glycated Hemoglobin with All-Cause and Cause-Specific Mortality - Circulation (2021). PMID: 33878278
Common Panels:Diabetes ScreenComprehensive Longevity PanelMetabolic Profile
View All Panels

Associated Longevity Guides & Clinical Calculators

Medicine 3.0

Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Hemoglobin A1c (HbA1c) into overall healthspan optimization.

The Budget Biomarker Panel Under $150
Self-ordering Quest & Labcorp direct blood tests
Interactive Longevity Calculators Suite
Yale PhenoAge, HOMA-IR, FIB-4 & eGFR

Related Metabolic & Glycemic Control Biomarkers

Fasting Blood Glucose
FBG · 75 - 85 mg/dL
Fasting Serum Insulin
Fasting Insulin · 2.0 - 5.0 μIU/mL
Homeostatic Model Assessment of Insulin Resistance
HOMA-IR · < 1.0
Serum Fructosamine
Fructosamine · 200 - 240 μmol/L
PreviousFasting Blood Glucose (FBG)Metabolic & Glycemic ControlNextFasting Serum Insulin (Fasting Insulin)Metabolic & Glycemic Control